News releases | Absci Corp

Year

21 Sep / 23

Absci Announces Speaker Lineup for Inaugural R&D Day, Including Renowned Global Business Leader Sandi Peterson and VP of Applied Research at NVIDIA Jonathan Cohen

VANCOUVER, Wash. and NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the speaker lineup for its inaugural R&D Day on Wednesday, October 4 th , 2023. The program will begin at 9:00 a.m.

06 Sep / 23

Absci to Host R&D Day on October 4, 2023

VANCOUVER, Wash. and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will host its first R&D Day on Wednesday, October 4 th , 2023 in New York City. The program will begin at 9:00 a.m.

28 Aug / 23

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. H.C. Wainwright 25 th Annual Global Investment Conference

14 Aug / 23

Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results

Entered into partnership with Google Ventures-backed biotech company to discover innovative new medicines Entered into collaboration with Caltech, supported by the Gates Foundation, to discover affordable HIV therapeutic vaccinations VANCOUVER, Wash. and NEW YORK, Aug.

14 Aug / 23

Absci Appoints Zach Jonasson, Ph.D., as Chief Financial Officer and Chief Business Officer

Addition of veteran biotech leader to further support Absci’s next stage of growth VANCOUVER, Wash., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Absci Corporation , a generative AI drug creation company, announced today that Zach Jonasson, Ph.D., has been appointed Chief Financial Officer (CFO) and Chief

10 Aug / 23

Absci and Caltech Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development

VANCOUVER, Wash., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI ), a generative AI drug creation company, today announced that leading researchers at the California Institute of Technology (Caltech) in conjunction with Absci, a leader in AI drug creation, received a grant from

01 Aug / 23

Absci to Participate in the UBS MedTech, Tools and Genomics Summit 2023

VANCOUVER, Wash. and NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming UBS MedTech, Tools and Genomics Summit 2023 in Dana Point, CA.

26 Jul / 23

Absci to Participate in the Canaccord Genuity 43rd Annual Growth Conference

VANCOUVER, Wash. and NEW YORK, July 26, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming Canaccord Genuity 43 rd Annual Growth Conference in Boston, MA.

15 Jun / 23

Absci to Participate in the Morgan Stanley 2nd Annual Biotechnology AI Summit

VANCOUVER, Wash. and NEW YORK, June 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming Morgan Stanley 2 nd Annual Biotechnology AI Summit in New York, NY.

06 Jun / 23

Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips

VANCOUVER, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of Frans van Houten to its Board of Directors. With his exceptional leadership experience and deep industry knowledge in the healthcare and technology

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 22